Your cart is currently empty!.
You may check out all the available products and buy some in the shop.
Continue Shopping
Edwards Lifesciences Corp (EW) (Q4FY24) – Innovation fuels growth, but headwinds demand caution
$232.00
EW's TAVR segment showed progress with the EARLY TAVR trial, which demonstrated better outcomes for asymptomatic severe aortic stenosis patients using the SAPIEN platform compared to standard monitoring.
Description
Description
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally.
The Surgical segment saw 2024 global sales of $981 million, a 6% increase year-over-year, with Q4 sales reaching $244 million, up 5% from last year.
Edwards Lifesciences Corp In the last 3 months the stock delivered a gain of 0.38% where the stock price increased to $71.80 as of 6th Mar 2025 from $71.53 as of 6th Dec 2024.
Executive Summary
• CrispIdea Forecast
– Income Statement
– Balance Sheet
– Cash Flow
– Common Size Ratio Analysis
– CrispIdea Segment Forecast
• Valuation & Historical Performance
– P/E Analysis
– CrispIdea Valuation
– Peer Comparison
– Ratio Analysis
– Economic Value-Added Analysis
– Du Pont Analysis
– CrispIdea Forecast Relative to Consensus
– Consensus Momentum
– Segment Performance
– Key Developments
– M&A Deals
• Ownership
• Stock Price Performance
• Crispidea Coverage
https://www.crispidea.com/report/edwards-lifesciences-equity-report-q3-24/
